Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.02, read 2026-10-28
Ethical passes the values gate
Price40.63 USD
Fair value24.28
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup39.35+3.3% to today ✓Accumulation gives way to Markup after a 17% rise in 2 weeks
2026-09-24Read Accumulation33.75+20.4% to today ✓Markup gives way to Accumulation
2026-08-22Read Markup33.91+19.8% to today ✓Distribution gives way to Markup after a 50% rise in 7 weeks
2026-07-02Read Distribution22.59+79.9% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Azenta, Inc. holds its Markup at $40.63. Consolidating, no directional conviction, held for 13 days.
As held on the ledger · 2026-10-28
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 13 days
Price at the screen
$40.63
Valuation
N/A trailing · 65.18 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.52
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.49%
Below 33%
Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.79%
Below 33%
Cash held in interest-bearing accounts and securities is 9.8% of assets, under the one-third limit.
Pass
Receivables
20.49%
Below 49%
Money owed to the company is 20.5% of assets, under the 49% limit.
Pass
Revenue purity
3.16%
Below 5%
Only 3.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Azenta, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 2%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AZTA's ethical verdict changes
Today AZTA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 40.2% above the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits −3% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Sample handler priced far beyond its real worth
Picture a firm that helps labs store and manage millions of biological samples across continents. Azenta does that job, yet the shares sit well above any sensible price. At twenty six dollars the stock carries a forward multiple of forty three times earnings for revenue that is barely growing and profits that remain deep in the red.
The gap to our fair value of seventeen dollars leaves a thirty six percent shortfall with no margin of safety. One percent top line growth and a negative twenty nine percent profit margin do not support the current valuation, even if five analysts still carry buy notes with a twenty eight dollar median target. Ethical screens clear, but that alone does not turn a stretched price into an opportunity.
High multiples on weak returns on equity and thin growth often signal a value trap rather than a bargain. Currency moves and life science spending cycles add further uncertainty. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AZTA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markup$36.01-1.4%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-10-18Markup$36.52-7.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-10-11Markup · changed$39.35+16.6%Entry 8
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-10-02Accumulation$33.75+0.0%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-08-22Markup · changed$33.91+29.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 29.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-22Distribution$26.29+16.4%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-18Distribution$22.59+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-03Distribution$22.59+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$22.59Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
